Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CVAC Stock Forecast 2025-2026
$5.12
Current Price
$1.15B
Market Cap
Buy 1
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to CVAC Price Targets
+8.1%
To High Target of $5.54
+8.1%
To Median Target of $5.53
-1.7%
To Low Target of $5.03
CVAC Price Momentum
-6.7%
1 Week Change
-1.7%
1 Month Change
+65.2%
1 Year Change
+50.1%
Year-to-Date Change
-10.5%
From 52W High of $5.72
+106.9%
From 52W Low of $2.48
📊 TOP ANALYST CALLS
Did CVAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CureVac is one of their latest high-conviction picks.
Latest CVAC Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CVAC has a neutral consensus with a median price target of $5.53 (ranging from $5.03 to $5.54). The overall analyst rating is Buy (7.0/10). Currently trading at $5.12, the median forecast implies a 8.1% upside. This outlook is supported by 1 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVAC Analyst Ratings
1
Buy
3
Hold
0
Sell
CVAC Price Target Range
Low
$5.03
Average
$5.53
High
$5.54
Current: $5.12
Latest CVAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 26, 2025 | UBS | Eliana Merle | Neutral | Downgrade | $5.50 |
| Jun 13, 2025 | Jefferies | Roger Song | Hold | Downgrade | $5.00 |
| May 28, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $10.00 |
| Apr 30, 2025 | UBS | Eliana Merle | Buy | Maintains | $12.00 |
| Feb 14, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $16.00 |
| Sep 16, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $16.00 |
| Aug 16, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $16.00 |
| Jul 3, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $18.00 |
| Apr 25, 2024 | Leerink Partners | Mani Foroohar | Market Perform | Downgrade | $4.00 |
| Apr 5, 2024 | Guggenheim | Evan Wang | Neutral | Reiterates | $N/A |
| Aug 21, 2023 | B of A Securities | Geoff Meacham | Underperform | Maintains | $8.00 |
| Jun 8, 2023 | SVB Securities | Mani Foroohar | Outperform | Initiates | $13.00 |
| Apr 26, 2023 | JMP Securities | Roy Buchanan | Outperform | Maintains | $24.00 |
| Jan 19, 2023 | UBS | Eliana Merle | Buy | Upgrade | $18.00 |
| Jan 9, 2023 | Jefferies | Eun Yang | Buy | Upgrade | $N/A |
| Nov 17, 2022 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $34.00 |
| Apr 22, 2022 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $37.00 |
| Jan 21, 2022 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $20.00 |
| Dec 31, 2021 | Deutsche Bank | Hold | Initiates | $N/A | |
| Oct 22, 2021 | Deutsche Bank | Hold | Initiates | $N/A |
CureVac N.V. (CVAC) Competitors
The following stocks are similar to CureVac based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CureVac N.V. (CVAC) Financial Data
CureVac N.V. has a market capitalization of $1.15B with a P/E ratio of 7.6x. The company generates $82.41M in trailing twelve-month revenue with a 182.1% profit margin.
Revenue growth is -89.0% quarter-over-quarter, while maintaining an operating margin of +573.0% and return on equity of +23.3%.
Valuation Metrics
Market Cap
$1.15B
Enterprise Value
$635.41M
P/E Ratio
7.6x
PEG Ratio
-0.4x
Price/Sales
16.3x
Growth & Margins
Revenue Growth (YoY)
-89.0%
Gross Margin
+99.3%
Operating Margin
+573.0%
Net Margin
+182.1%
EPS Growth
-19.2%
Financial Health
Cash/Price Ratio
+44.9%
Current Ratio
3.7x
Debt/Equity
4.0x
ROE
+23.3%
ROA
+20.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CureVac N.V. (CVAC) Business Model
About CureVac N.V.
What They Do
Develops transformative mRNA-based medicines and vaccines.
Business Model
CureVac generates revenue through the development and commercialization of mRNA-based vaccines and therapeutics. The company engages in partnerships with larger pharmaceutical firms and conducts clinical trials to advance its products, focusing on areas such as infectious diseases and oncology.
Additional Information
Founded in 2000 and based in Tübingen, Germany, CureVac has gained prominence for its role in vaccine development, especially during the COVID-19 pandemic. Its proprietary technology platform enables it to leverage mRNA's capabilities, positioning the company as a significant player in biotechnology and precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
825
CEO
Dr. Alexander Zehnder M.B.A., M.D.
Country
Germany
IPO Year
2020
Website
www.curevac.comCureVac N.V. (CVAC) Latest News & Analysis
Latest News
Quick Summary
BioNTech has satisfied the minimum condition for its offer, with 81.74% of CureVac's shares tendered. The subsequent offering period ends on December 18, 2025.
Why It Matters
BioNTech's successful tender offer for CureVac shares signals strong investor interest and could lead to strategic growth, impacting share prices and market positioning in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CureVac N.V. will hold an Extraordinary General Meeting of Shareholders on November 25, 2025, at 8:00 AM EST, featuring key company executives.
Why It Matters
CureVac's shareholder call could signal key updates on strategy or performance, impacting investor sentiment and stock valuation. Attendance by executives suggests potential for significant announcements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CureVac N.V. announced the voting results from its Extraordinary General Meeting (EGM) on November 25, 2025, as it continues to develop mRNA-based medicines.
Why It Matters
CureVac's EGM results may signal strategic direction changes, impacting investor sentiment and stock performance in the biotech sector, especially around mRNA innovations.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
BioNTech's acquisition of CureVac has received clearance from the German Federal Cartel Office. The exchange offer runs from Oct 21 to Dec 3, 2025, with strong cash reserves reported at €416.1 million.
Why It Matters
The clearance for BioNTech's acquisition of CureVac signals potential growth and synergy in biotech, while the strong cash position suggests stability, influencing investor confidence and stock valuation.
Source: Accesswire
Market Sentiment:
Neutral
CureVac: The Hidden Value Of The mRNA Wallet
2 months ago
Quick Summary
CureVac specializes in mRNA drugs for oncology and vaccines, holding over 1,000 patents. Its value is driven by research quality and patent strength rather than current revenues.
Why It Matters
CureVac's extensive mRNA patent portfolio and long research history enhance its valuation potential, signaling strong future growth prospects in biotech innovation.
Source: Seeking Alpha
Market Sentiment:
Positive
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
3 months ago
Quick Summary
CureVac reported a strong cash position of €392.7 million as of June 30, 2025, and announced BioNTech's intent to acquire it, resolving patent disputes and advancing cancer treatments.
Why It Matters
CureVac's acquisition by BioNTech enhances mRNA capabilities, resolving patent disputes boosts market confidence, and strong cash reserves support ongoing R&D, positioning both companies for growth.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CVAC Stock
What is CureVac N.V.'s (CVAC) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, CureVac N.V. (CVAC) has a median price target of $5.53. The highest price target is $5.54 and the lowest is $5.03.
Is CVAC stock a good investment in 2026?
According to current analyst ratings, CVAC has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CVAC stock?
Wall Street analysts predict CVAC stock could reach $5.53 in the next 12 months. This represents a 8.1% increase from the current price of $5.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CureVac N.V.'s business model?
CureVac generates revenue through the development and commercialization of mRNA-based vaccines and therapeutics. The company engages in partnerships with larger pharmaceutical firms and conducts clinical trials to advance its products, focusing on areas such as infectious diseases and oncology.
What is the highest forecasted price for CVAC CureVac N.V.?
The highest price target for CVAC is $5.54 from at , which represents a 8.1% increase from the current price of $5.12.
What is the lowest forecasted price for CVAC CureVac N.V.?
The lowest price target for CVAC is $5.03 from at , which represents a -1.7% decrease from the current price of $5.12.
What is the overall CVAC consensus from analysts for CureVac N.V.?
The overall analyst consensus for CVAC is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $5.53.
How accurate are CVAC stock price projections?
Stock price projections, including those for CureVac N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 7:06 AM UTC